未登录

C

Chi Meng

Nanjing University

H指数:17

被引数:875

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Activation of Lysozyme with Robust Flavoenzyme Activity by Amyloid Fibrillation

通过淀粉样蛋白纤维化激活具有强黄素酶活性的溶菌酶

ACS Applied Bio Materials

IF4.7

2026-04-230

PRE

Activatable Self-Reporting Cyclization Reaction for In-Cell Synthesis of Cyclocyanines

可激活的自报告环化反应用于细胞内合成环状菁染料

IF7.4

2025-11-170

OAAI

A new perspective on intracellular redox environment-mediated innovative photodynamic therapy

细胞内氧化还原环境介导的新型光动力疗法的全新视角

IF4.2

2025-10-020

PRE

Recent Advances for Synthesis and Bioapplications of Polymethine Cyanines

近期聚甲炔类菁染料的合成及其生物应用进展

ASIAN JOURNAL OF ORGANIC CHEMISTRY

IF2.7

2025-04-110

PRE

Octreotide modified self-assembly Chlorin e6 nanoparticles with redox responsivity and active targeting for highly selective pancreatic neuroendocrine neoplasms photodynamic therapy

MICROCHEMICAL JOURNAL

IF5.1

2025-01-010

PRE

Recent advances for enhanced photodynamic therapy: from new mechanisms to innovative strategies

CHEMICAL SCIENCE

IF7.4

2024-01-015

OAAI

A versatile supramolecular nanoagent for three-pronged boosting chemodynamic therapy

JOURNAL OF COLLOID AND INTERFACE SCIENCE

IF9.7

2023-10-013

PRE

TME-targeting nano-theranostic agent for NIR fluorescence diagnosis and O2-economized PDT-based multimodal synergistic therapy

MATERIALS & DESIGN

IF7.9

2023-09-013

OAAI

Acidic tumor microenvironment-activatable fluorescent diagnostic probe for the rapid identification and resection of human tumors via spraying

酸性肿瘤微环境可激活的荧光诊断探针，用于通过喷雾快速识别和切除人类肿瘤

BIOSENSORS & BIOELECTRONICS

IF10.5

2023-08-018

PRE

Prediction of immune and targeted drug efficacy in pain-related risk subtypes for bladder cancer patients

IF3.6

2023-07-011

OAAI

A random forest-based metabolic risk model to assess the prognosis and metabolism-related drug targets in ovarian cancer

COMPUTERS IN BIOLOGY AND MEDICINE

IF6.3

2023-02-0116

PRE

Novel pH-activatable NIR fluorogenic spray mediated near-instant and precise tumor margins identification in human cancer tissues for surgical resection

IF13.3

2023-01-011

OAAI

Characterized the diversity of ABCB1 subtypes in immunogenomic landscape for predicting the drug response in breast cancer

IF4.3

2022-08-013

PRE

Redox-Activatable Theranostic Co-Prodrug for Precise Tumor Diagnosis and Selective Combination Chemotherapy

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2022-07-2511

PRE

Study on distortion energy and stability of gob floor based on stress deviator field

ENERGY SCIENCE & ENGINEERING

IF3.4

2022-04-217

OAAI

Recent development of BTK-based dual inhibitors in the treatment of cancers

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2022-04-0120

PRE

A Double-Locked and Enzyme/pH-Activated Theranostic Agent for Accurate Tumor Imaging and Therapy

IF4.6

2022-01-107

OAAI

TME-targeting theranostic agent uses NIR tracking for tumor diagnosis and surgical resection and acts as chemotherapeutic showing enhanced efficiency and minimal toxicity

IF13.3

2022-01-0110

OAAI

A Derivative of Piperlongumine and Ligustrazine as a Potential Thioredoxin Reductase Inhibitor in Drug-Resistant Hepatocellular Carcinoma

JOURNAL OF NATURAL PRODUCTS

IF3.6

2021-11-2120

PRE

GSH/ROS Dual-Responsive Supramolecular Nanoparticles Based on Pillar[6]arene and Betulinic Acid Prodrug for Chemo-Chemodynamic Combination Therapy

IF4.6

2021-09-299

OAAI